According to filings with the U.S. Securities and Exchange Commission, CG Oncology is raising $289,000,000.00 in new funding. About CG Oncology: CG Oncology is a privately held oncolytic immunotherapy company focused on developing bladder-saving therapeutics for patients with bladder cancer. At CG Oncology we see a world where urologic cancer patients can benefit from our innovative therapies to live and work with dignity and an enhanced quality of life. Our lead candidate, CG0070, is an intravesically delivered oncolytic immunotherapy agent in a Phase 3 trial for the treatment of BCG-unresponsive non-muscle invasive bladder cancer. CG0070 is also in a Phase 2 study in combination with KEYTRUDA (pembrolizumab) in the same indication. Other types of bladder cancer are being evaluated with CG0070 in combination with OPDIVO (nivolumab).

To learn more about CG Oncology, visit http://www.cgoncology.com/

Contact:
Arthur Kuan, Chairman and Chief Executive Officer
949-409-3700
https://www.linkedin.com/in/arthurkuan/

SOURCE: http://www.intelligence360.io
Copyright (c) 2024 SI360 Inc. All rights reserved.